Jörneskog G - Search Results

1

Comparison of two laboratory assays for the investigation of fibrin gel porosity.

Antovic A, Jörneskog G, Wallen NH. Antovic A, et al. Among authors: jorneskog g. Thromb Haemost. 2007 Dec;98(6):1386-8. doi: 10.1160/th07-06-0390. Thromb Haemost. 2007. PMID: 18064345 No abstract available.

2

Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion.

Jörneskog G, Hansson LO, Wallen NH, Yngen M, Blombäck M. Jörneskog G, et al. J Thromb Haemost. 2003 Jun;1(6):1195-201. doi: 10.1046/j.1538-7836.2003.00301.x. J Thromb Haemost. 2003. PMID: 12871319 Free article.

3

Fibrin clot properties and haemostatic function in men and women with type 1 diabetes.

Tehrani S, Jörneskog G, Ågren A, Lins PE, Wallén H, Antovic A. Tehrani S, et al. Among authors: jorneskog g. Thromb Haemost. 2015 Feb;113(2):312-8. doi: 10.1160/TH14-05-0404. Epub 2014 Oct 16. Thromb Haemost. 2015. PMID: 25318636

4

Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.

Antovic JP, Yngen M, Ostenson CG, Antovic A, Wallen HN, Jorneskög G, Blombäck M. Antovic JP, et al. Among authors: jorneskog g. Blood Coagul Fibrinolysis. 2003 Sep;14(6):551-6. doi: 10.1097/00001721-200309000-00006. Blood Coagul Fibrinolysis. 2003. PMID: 12960608

5

Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.

Tehrani S, Mobarrez F, Antovic A, Santesson P, Lins PE, Adamson U, Henriksson P, Wallén NH, Jörneskog G. Tehrani S, et al. Among authors: jorneskog g. Thromb Res. 2010 Sep;126(3):e225-31. doi: 10.1016/j.thromres.2010.05.023. Epub 2010 Jul 15. Thromb Res. 2010. PMID: 20637495 Clinical Trial.

6

Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.

Mobarrez F, He S, Bröijersen A, Wiklund B, Antovic A, Antovic J, Egberg N, Jörneskog G, Wallén H. Mobarrez F, et al. Among authors: jorneskog g. Thromb Haemost. 2011 Aug;106(2):344-52. doi: 10.1160/TH10-12-0810. Epub 2011 May 26. Thromb Haemost. 2011. PMID: 21614411 Clinical Trial.

7

High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetes.

Tehrani S, Antovic A, Mobarrez F, Mageed K, Lins PE, Adamson U, Wallén HN, Jörneskog G. Tehrani S, et al. Among authors: jorneskog g. Diabetes Care. 2012 Feb;35(2):404-8. doi: 10.2337/dc11-1302. Epub 2011 Dec 6. Diabetes Care. 2012. PMID: 22148098 Free PMC article. Clinical Trial.

8

Infusion of angiotensin II increases fibrinolysis in healthy individuals but not in patients with familial combined hyperlipidemia.

Ekholm M, Kahan T, Jörneskog G, Bröijersén A, Wallén NH. Ekholm M, et al. Among authors: jorneskog g. Blood Coagul Fibrinolysis. 2016 Jan;27(1):113-6. doi: 10.1097/MBC.0000000000000393. Blood Coagul Fibrinolysis. 2016. PMID: 26340459

9

Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo.

Ekholm M, Kahan T, Jörneskog G, Bröijersen A, Wallén NH. Ekholm M, et al. Among authors: jorneskog g. Thromb Res. 2009 May;124(1):110-5. doi: 10.1016/j.thromres.2008.12.040. Epub 2009 Feb 4. Thromb Res. 2009. PMID: 19195683

10

Altered vascular responses to circulating angiotensin II in familial combined hyperlipidemia.

Jörneskog G, Kahan T, Ekholm M, Bröijersén A, Wallén NH. Jörneskog G, et al. J Cardiovasc Med (Hagerstown). 2008 Oct;9(10):1037-44. doi: 10.2459/JCM.0b013e32830a48bd. J Cardiovasc Med (Hagerstown). 2008. PMID: 18799967

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

78 results

Search Page

Filters